CR10014A - Derivados de 3-alquilazetidina sustituidos con heterociclos. - Google Patents
Derivados de 3-alquilazetidina sustituidos con heterociclos.Info
- Publication number
- CR10014A CR10014A CR10014A CR10014A CR10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A CR 10014 A CR10014 A CR 10014A
- Authority
- CR
- Costa Rica
- Prior art keywords
- alquilazetidina
- heterocicles
- derivatives
- substituted
- receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos novedosos de la fórmula estructural (I) son antagonistas y/o agonistas inversos del receptor cannabinoide-1 (CB1) y son útiles en el tratamiento, prevención y supresión de enfermedades mediadas por el receptor CB1. Los compuestos de la presente invención son útiles como fármacos que actúan a nivel central en el tratamiento de psicosis, deficiencias de la memoria, trastornos cognitivos, enfermedad de Alzheimer, migraña, neuropatía, trastornos neuroinflamatorios que incluyen esclerosis múltiple.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74018305P | 2005-11-28 | 2005-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10014A true CR10014A (es) | 2008-07-29 |
Family
ID=37779312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10014A CR10014A (es) | 2005-11-28 | 2008-05-22 | Derivados de 3-alquilazetidina sustituidos con heterociclos. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1954692A1 (es) |
| KR (1) | KR20080073721A (es) |
| AR (1) | AR058199A1 (es) |
| BR (1) | BRPI0619018A2 (es) |
| CR (1) | CR10014A (es) |
| DO (1) | DOP2006000261A (es) |
| EC (1) | ECSP088477A (es) |
| IL (1) | IL191586A0 (es) |
| MA (1) | MA30086B1 (es) |
| NO (1) | NO20082919L (es) |
| PE (1) | PE20070647A1 (es) |
| RU (1) | RU2008126248A (es) |
| SV (1) | SV2009002917A (es) |
| TW (1) | TW200804317A (es) |
| WO (1) | WO2007062193A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2703465A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Synthesis and crystalline forms of cb-1 antagonist/inverse agonist |
| WO2012031220A2 (en) | 2010-09-03 | 2012-03-08 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| KR20060019587A (ko) * | 2003-06-11 | 2006-03-03 | 머크 앤드 캄파니 인코포레이티드 | 치환된 3-알킬 및 3-알케닐 아제티딘 유도체 |
| US20090306037A1 (en) * | 2005-05-02 | 2009-12-10 | Merck & Co., Inc. | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity |
-
2006
- 2006-11-20 AR ARP060105076A patent/AR058199A1/es unknown
- 2006-11-22 RU RU2008126248/04A patent/RU2008126248A/ru not_active Application Discontinuation
- 2006-11-22 TW TW095143274A patent/TW200804317A/zh unknown
- 2006-11-22 WO PCT/US2006/045328 patent/WO2007062193A1/en not_active Ceased
- 2006-11-22 EP EP06838347A patent/EP1954692A1/en not_active Withdrawn
- 2006-11-22 BR BRPI0619018A patent/BRPI0619018A2/pt not_active IP Right Cessation
- 2006-11-22 KR KR1020087012880A patent/KR20080073721A/ko not_active Withdrawn
- 2006-11-23 PE PE2006001495A patent/PE20070647A1/es not_active Application Discontinuation
- 2006-11-23 DO DO2006000261A patent/DOP2006000261A/es unknown
-
2008
- 2008-05-20 IL IL191586A patent/IL191586A0/en unknown
- 2008-05-22 CR CR10014A patent/CR10014A/es not_active Application Discontinuation
- 2008-05-27 EC EC2008008477A patent/ECSP088477A/es unknown
- 2008-05-28 SV SV2008002917A patent/SV2009002917A/es not_active Application Discontinuation
- 2008-06-25 MA MA31075A patent/MA30086B1/fr unknown
- 2008-06-27 NO NO20082919A patent/NO20082919L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200804317A (en) | 2008-01-16 |
| WO2007062193A1 (en) | 2007-05-31 |
| ECSP088477A (es) | 2008-06-30 |
| IL191586A0 (en) | 2008-12-29 |
| EP1954692A1 (en) | 2008-08-13 |
| AR058199A1 (es) | 2008-01-23 |
| PE20070647A1 (es) | 2007-08-11 |
| SV2009002917A (es) | 2009-02-19 |
| RU2008126248A (ru) | 2010-01-10 |
| MA30086B1 (fr) | 2008-12-01 |
| NO20082919L (no) | 2008-08-27 |
| DOP2006000261A (es) | 2007-07-15 |
| BRPI0619018A2 (pt) | 2016-11-29 |
| KR20080073721A (ko) | 2008-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR7432A (es) | Amidas sustituidas activas del receptor de canabinoide-1 | |
| NI201100084A (es) | Antagonistas del receptor de orexina de isonicotinamida. | |
| DK2049529T3 (da) | Substituerede diazepan-orexin-receptor- antagonister | |
| NI200900193A (es) | Antagonistas piridil piperidina del receptor de orexina | |
| ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
| CR20130214A (es) | Antagonistas del receptor del cgpr de piperidinona carboxamida azaindano | |
| CY1111977T1 (el) | Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
| AR036302A1 (es) | Asociacion de un antagonista del receptor cb1 con un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen, y su utilizacion en el tratamiento de la enfermedad de parkinson | |
| ATE535514T1 (de) | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| MX2020013085A (es) | Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos. | |
| MX2009005712A (es) | Antagonistas de receptor de orexina de diazepam sustituido. | |
| ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| UA100974C2 (ru) | Соединения замещенных диазепанов как антагонисты орексиновых рецепторов | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| CL2008002506A1 (es) | Compuestos derivados de bencimidazol sustituido, procedimiento de preparacion, composicion farmaceutica, util en el tratamiento de enfermedades moduladas con antagonistas del receptor fxr, en particular para el tratamiento de los niveles incrementados de lipidos y/o colesterol, enfermedad aterosclerotica, diabetes, cancer, parkinson, alzheimer. | |
| AR036303A1 (es) | Asociacion de un antagonista del receptor cb1 con un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen, y su utilizacion para el tratamiento de la enfermedad de parkinson | |
| CY1113820T1 (el) | Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
| ECSP088477A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
| GEAP202115141A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| SV2011003839A (es) | Agentes antifungicos | |
| ATE466853T1 (de) | Cgrp-rezeptorantagonisten | |
| NZ747778A (en) | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist | |
| CY1122312T1 (el) | Παραγωγα 4-υδροξυ-2-φαινυλο-4-1,3-θειαζολ-5-υλομεθανονης σαν ανταγωνιστες tprm8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |